FDA approves Ionis drug Tryngolza for severe hypertriglyceridemia
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/23/2026
- Wall St falls as Big Tech earnings rekindle AI spending worries; oil hits $100
- Google increases capex forecast again after cloud-driven quarterly beat
- As Musk pivots beyond cars, Tesla’s autos engine is under strain
- RTX stock jumps as company lifts guidance after Q2 beat
- Dollar hits new 40-year high versus yen, euro lower after ECB decision
TRYNGOLZA® (olezarsen) approved by the FDA as the first and only treatment to reduce triglycerides and the risk of acute pancreatitis in patients with severe hypertriglyceridemia (sHTG)
June 24, 2026 2:37 PM EDTProven to deliver significant and robust triglyceride reductions
Only treatment for sHTG indicated to reduce the risk of acute pancreatitis
Ionis first independent commercial launch in a prevalent condition
Ionis to host webcast today at 3:30 p.m. ET
CARLSBAD, Calif.--(BUSINESS... More
